Delivers Third Quarter Net Sales of $753.1 Million, Driven by Acthar® Gel (repository corticotropin injection) Growth and the Inclusion of Two Months of ...
Keenova Focused on Advancing Therapies to Address Unmet Patient Needs Company Intends to Pursue Public Equity Listing in 2026 DUBLIN, Nov. 10, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback